1. Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer. Issue 9 (8th August 2021) Authors: Yang, Zhang; Liang, Shun‐Qing; Saliakoura, Maria; Yang, Haitang; Vassella, Eric; Konstantinidou, Georgia; Tschan, Mario; Hegedüs, Balazs; Zhao, Liang; Gao, Yanyun; Xu, Duo; Deng, Haibin; Marti, Thomas M; Kocher, Gregor J; Wang, Wenxiang; Schmid, Ralph A; Peng, Ren‐Wang Journal: EMBO molecular medicine Issue: Volume 13:Issue 9(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗